Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand.

Ali R, Brown W, Purdy SC, Davisson VJ, Wendt MK.

Cell Death Dis. 2018 Sep 24;9(10):976. doi: 10.1038/s41419-018-1034-7.

2.

Hyaluronic acid, CD44 and RHAMM regulate myoblast behavior during embryogenesis.

Leng Y, Abdullah A, Wendt MK, Calve S.

Matrix Biol. 2018 Aug 18. pii: S0945-053X(18)30102-1. doi: 10.1016/j.matbio.2018.08.008. [Epub ahead of print]

PMID:
30130585
3.

Pyruvate carboxylase supports the pulmonary tropism of metastatic breast cancer.

Shinde A, Wilmanski T, Chen H, Teegarden D, Wendt MK.

Breast Cancer Res. 2018 Jul 13;20(1):76. doi: 10.1186/s13058-018-1008-9.

4.

Autocrine Fibronectin Inhibits Breast Cancer Metastasis.

Shinde A, Libring S, Alpsoy A, Abdullah A, Schaber JA, Solorio L, Wendt MK.

Mol Cancer Res. 2018 Oct;16(10):1579-1589. doi: 10.1158/1541-7786.MCR-18-0151. Epub 2018 Jun 22.

PMID:
29934326
5.

Analytical Pipeline for Discovery and Verification of Glycoproteins from Plasma-Derived Extracellular Vesicles as Breast Cancer Biomarkers.

Chen IH, Aguilar HA, Paez Paez JS, Wu X, Pan L, Wendt MK, Iliuk AB, Zhang Y, Tao WA.

Anal Chem. 2018 May 15;90(10):6307-6313. doi: 10.1021/acs.analchem.8b01090. Epub 2018 Apr 23.

PMID:
29629753
6.

Regulation of epithelial-mesenchymal transition and metastasis by TGF-β, P-bodies, and autophagy.

Hardy SD, Shinde A, Wang WH, Wendt MK, Geahlen RL.

Oncotarget. 2017 Oct 17;8(61):103302-103314. doi: 10.18632/oncotarget.21871. eCollection 2017 Nov 28.

7.

Selective Inhibition of STAT3 Phosphorylation Using a Nuclear-Targeted Kinase Inhibitor.

Bartolowits MD, Brown W, Ali R, Pedley AM, Chen Q, Harvey KE, Wendt MK, Davisson VJ.

ACS Chem Biol. 2017 Sep 15;12(9):2371-2378. doi: 10.1021/acschembio.7b00341. Epub 2017 Aug 18.

8.

The paradoxical functions of EGFR during breast cancer progression.

Ali R, Wendt MK.

Signal Transduct Target Ther. 2017;2. pii: 16042. doi: 10.1038/sigtrans.2016.42. Epub 2017 Jan 20.

9.

Phosphoproteins in extracellular vesicles as candidate markers for breast cancer.

Chen IH, Xue L, Hsu CC, Paez JS, Pan L, Andaluz H, Wendt MK, Iliuk AB, Zhu JK, Tao WA.

Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3175-3180. doi: 10.1073/pnas.1618088114. Epub 2017 Mar 7.

10.

FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.

Brown WS, Akhand SS, Wendt MK.

Oncotarget. 2016 Dec 13;7(50):83424-83436. doi: 10.18632/oncotarget.13117.

11.

Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer.

Brown WS, Tan L, Smith A, Gray NS, Wendt MK.

Mol Cancer Ther. 2016 Sep;15(9):2096-106. doi: 10.1158/1535-7163.MCT-16-0136. Epub 2016 Jul 1.

12.

Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.

Parvani JG, Davuluri G, Wendt MK, Espinosa C, Tian M, Danielpour D, Sossey-Alaoui K, Schiemann WP.

Neoplasia. 2015 Mar;17(3):317-28. doi: 10.1016/j.neo.2015.02.003.

13.

The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6.

Wendt MK, Williams WK, Pascuzzi PE, Balanis NG, Schiemann BJ, Carlin CR, Schiemann WP.

Neoplasia. 2015 Jan;17(1):124-33. doi: 10.1016/j.neo.2014.11.009.

14.

Detection of Lysyl Oxidase-Like 2 (LOXL2), a Biomarker of Metastasis from Breast Cancers Using Human Blood Samples.

Janyasupab M, Lee YH, Zhang Y, Liu CW, Cai J, Popa A, Samia AC, Wang KW, Xu J, Hu CC, Wendt MK, Schiemann BJ, Thompson CL, Yen Y, Schiemann WP, Liu CC.

Recent Pat Biomark. 2015;5(2):93-100. doi: 10.2174/2210309005666150804195033.

15.

Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy: an inflammatory situation.

Brown WS, Wendt MK.

Breast Cancer Res. 2014 Sep 23;16(5):448. doi: 10.1186/s13058-014-0448-0.

16.

STAT3 and epithelial-mesenchymal transitions in carcinomas.

Wendt MK, Balanis N, Carlin CR, Schiemann WP.

JAKSTAT. 2014 Jan 1;3(1):e28975. doi: 10.4161/jkst.28975. Epub 2014 Apr 29. Review.

17.

Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers.

Wendt MK, Taylor MA, Schiemann BJ, Sossey-Alaoui K, Schiemann WP.

Breast Cancer Res. 2014 Mar 11;16(2):R24. doi: 10.1186/bcr3623.

18.

Longitudinal Bioluminescent Quantification of Three Dimensional Cell Growth.

Wendt MK, Schiemann WP.

Bio Protoc. 2013 Dec 5;3(23). pii: e993.

19.

Upregulated WAVE3 expression is essential for TGF-β-mediated EMT and metastasis of triple-negative breast cancer cells.

Taylor MA, Davuluri G, Parvani JG, Schiemann BJ, Wendt MK, Plow EF, Schiemann WP, Sossey-Alaoui K.

Breast Cancer Res Treat. 2013 Nov;142(2):341-53. doi: 10.1007/s10549-013-2753-1. Epub 2013 Nov 7.

20.

Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.

Balanis N, Wendt MK, Schiemann BJ, Wang Z, Schiemann WP, Carlin CR.

J Biol Chem. 2013 Jun 21;288(25):17954-67. doi: 10.1074/jbc.M113.475277. Epub 2013 May 7.

21.

TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer.

Wendt MK, Schiemann BJ, Parvani JG, Lee YH, Kang Y, Schiemann WP.

Oncogene. 2013 Apr 18;32(16):2005-15. doi: 10.1038/onc.2012.230. Epub 2012 Jun 18.

22.

In vivo dual substrate bioluminescent imaging.

Wendt MK, Molter J, Flask CA, Schiemann WP.

J Vis Exp. 2011 Oct 11;(56). pii: 3245. doi: 10.3791/3245.

23.

β3 integrin-EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells.

Balanis N, Yoshigi M, Wendt MK, Schiemann WP, Carlin CR.

Mol Biol Cell. 2011 Nov;22(22):4288-301. doi: 10.1091/mbc.E10-08-0700. Epub 2011 Sep 21.

24.

Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression.

Wendt MK, Tian M, Schiemann WP.

Cell Tissue Res. 2012 Jan;347(1):85-101. doi: 10.1007/s00441-011-1199-1. Epub 2011 Jun 21. Review.

25.

Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer.

Wendt MK, Taylor MA, Schiemann BJ, Schiemann WP.

Mol Biol Cell. 2011 Jul 15;22(14):2423-35. doi: 10.1091/mbc.E11-04-0306. Epub 2011 May 25.

26.

CXCL12 chemokine expression and secretion regulates colorectal carcinoma cell anoikis through Bim-mediated intrinsic apoptosis.

Drury LJ, Wendt MK, Dwinell MB.

PLoS One. 2010 Sep 22;5(9):e12895. doi: 10.1371/journal.pone.0012895.

27.

Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression.

Wendt MK, Smith JA, Schiemann WP.

Oncogene. 2010 Dec 9;29(49):6485-98. doi: 10.1038/onc.2010.377. Epub 2010 Aug 30.

28.

Mechanisms of the epithelial-mesenchymal transition by TGF-beta.

Wendt MK, Allington TM, Schiemann WP.

Future Oncol. 2009 Oct;5(8):1145-68. doi: 10.2217/fon.09.90. Review.

29.

p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity.

Wendt MK, Smith JA, Schiemann WP.

J Biol Chem. 2009 Dec 4;284(49):34145-56. doi: 10.1074/jbc.M109.023614. Epub 2009 Oct 12.

30.

Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.

Wendt MK, Schiemann WP.

Breast Cancer Res. 2009;11(5):R68. doi: 10.1186/bcr2360.

31.

Constitutive CXCL12 expression induces anoikis in colorectal carcinoma cells.

Wendt MK, Drury LJ, Vongsa RA, Dwinell MB.

Gastroenterology. 2008 Aug;135(2):508-17. doi: 10.1053/j.gastro.2008.05.033. Epub 2008 May 15.

32.

Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease.

Zimmerman NP, Vongsa RA, Wendt MK, Dwinell MB.

Inflamm Bowel Dis. 2008 Jul;14(7):1000-11. doi: 10.1002/ibd.20480. Review.

33.

Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells.

Wendt MK, Cooper AN, Dwinell MB.

Oncogene. 2008 Feb 28;27(10):1461-71. Epub 2007 Sep 3.

PMID:
17724466
34.

Rho activation regulates CXCL12 chemokine stimulated actin rearrangement and restitution in model intestinal epithelia.

Moyer RA, Wendt MK, Johanesen PA, Turner JR, Dwinell MB.

Lab Invest. 2007 Aug;87(8):807-17. Epub 2007 Jun 18.

35.

Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis.

Wendt MK, Johanesen PA, Kang-Decker N, Binion DG, Shah V, Dwinell MB.

Oncogene. 2006 Aug 17;25(36):4986-97. Epub 2006 Mar 27.

36.

CXCL12 activation of CXCR4 regulates mucosal host defense through stimulation of epithelial cell migration and promotion of intestinal barrier integrity.

Smith JM, Johanesen PA, Wendt MK, Binion DG, Dwinell MB.

Am J Physiol Gastrointest Liver Physiol. 2005 Feb;288(2):G316-26. Epub 2004 Sep 9.

Supplemental Content

Loading ...
Support Center